SureTrader SureTrader
Home > Boards > US Listed > Biotechs >

Bio-Path Holdings Inc. (BPTH)

BPTH RSS Feed
Add BPTH Price Alert      Hide Sticky   Hide Intro
Moderator: SJSTOCKSHARK
Search This Board:
Last Post: 12/6/2016 6:33:10 PM - Followers: 36 - Board type: Free - Posts Today: 0
Bio-path Holdings Inc.

Company Description:

Bio-Path is engaged in the business of financing and commercializing novel cancer therapeutics acquired from MD Anderson Cancer Center. Their first Antisense drug BP-1001 has completed a combination (with LDAC) safety phase  8 cohort for treatment of AML. No toxicity was seen. 5 out of 6 patients acheived at least partial remission. 50% had total remission! The company has completed the review by the FDA for this drug to begin phase II. The patient dosing has begun at trials which will occur at up to 8 sites or more, including MD Anderson, Baylor and University of Kansas.


Bio-Path Holdings is focused on antisense drugs which work at a cellular level to interrupt protein production by the diseased cell. The lead drug is BP1001 targeting the Grb-2 protein. Several years ago Gilead attempted to produce viable antisense drugs unsuccessfully because of high toxicity caused by their cationic (positively charged) liposome delivery system. Bio Path Holdings' delivery system is a small molecule neutral liposome system. Through the 8 cohort of phase 1 (treating different types of leukemia) there has been absolutely no toxicity. Testing performed by Bio Path demonstrates an uptake of the drug at a cellular level. The pErk results demonstrate not only a 50+% knockdown of the target protein but shows the pathway was shut down validating our delivery system. With the completion of the combination safety trials with LDAC and FDA approval, phase 2 has begun and is accepting patients.  This trial will occur at several sites. The purpose of phase 2 will be to test the effectiveness of the drug. The company may explore FDA accelerated status after testing is complete on 19 additional patients which is expected to occur in mid 2017. A CML combination drug safety study for BP1001 is also expected to be completed by mid 2017.
 
Bio-Path Holdings will also begin phase 1 testing of their antisense drug BP1001 on certain types of breast cancer which the date have been resistant to treatment.  Additionally, BPTH is initiating development of a second drug BP1002 targeting Bcl-2 for Follicular Lymphoma. An IND for BP1002 is projected for early 2017.

The company has entered into a sponsored research agreement with the University of Texas Southwestern Medical Center to evaluate BPTH's pipeline for efficacy in down-regulating the immune response using systemic lupus erythematosus (SLE) as a model. Bio-Path has entered into a sponsored research agreement with Thomas Jefferson University to investigate DNAbilize™ antisense DNA technology for the development of a brain cancer immunotherapy that works by activating the patient’s own immune system to fight their cancer. Also, BPTH has entered into a sponsored research agreement with MD Anderson to evaluate the ability of its pipeline to modulate pancreatic cancer.


http://www.biopathholdings.com


While antisense drugs fell out of favor following Gilead's failed efforts there is now renewed interest.  Ionis established partnerships with Biogen Idec and GlaxoSmithKline for their antisense technology. If Bio-Path holdings proves the validity of their delivery system, I would expect similar partnerships.

This link to the company website describes their novel delivery technology:


http://biopathholdings.com/technology/


The company was founded on the technology from M.D. Anderson Cancer Center at the University of Texas in Houston. M.D. Anderson was the largest shareholder. After raising an additional 10 million dollars the company has $11+ million in cash. These funds should allow the company to start phase II testing of their antisense drug BP1001 on leukemia and begin phase I testing for breast cancer. The company has an "at the market" credit facility in place with Cantor Fitzgerald to raise another $25 million.

 
Bio-Path Holdings do not manufacture their drug but uses contractors. Once the efficacy of BP1001 is established, I would anticipate a manufacturing partnership will occur. The CEO says the company has now ramped up their structure as they are a phase 2 developmental company.
 
BPTH is traded on the NASDAQ.

Here is the link to the recent peer paper prepared by their experts:

http://www.biopathholdings.com/pdf/PeerExpertOpinion20150107.pdf

Analyst target price: Maxim $2, Zacks $3.50 and Rodman & Renshaw $5
                        
 
 
 
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
BPTH
Current Price
Volume:
Bid Ask Day's Range
SureTrader
PostSubject
#2310   This article although dated (2007) show the importance SJSTOCKSHARK 12/06/16 06:33:10 PM
#2309   Cviolin, Bingo. This was initially a traditional IRA SJSTOCKSHARK 12/06/16 05:47:00 PM
#2308   Roth IRA is tax free on anything pricipal, craiviolin 12/06/16 05:24:50 PM
#2307   A more detailed news release. It looks like SJSTOCKSHARK 12/06/16 05:13:24 PM
#2306   GP, I also wondered why there was no SJSTOCKSHARK 12/06/16 04:24:37 PM
#2305   Dec 6 (Reuters) - Bio Path Holdings Inc(BPTH) SJSTOCKSHARK 12/06/16 04:18:30 PM
#2304   You're right, SJ, some gleevec resistant patients will Gpheart2016 12/06/16 02:35:20 PM
#2303   "08:10 AM EST, 12/06/2016 (MT Newswires) -- Bio-Path SJSTOCKSHARK 12/06/16 12:07:35 PM
#2302   Nice, smart move ! too simple 12/01/16 12:26:51 PM
#2301   Simple, To avoid taxes on the my gains SJSTOCKSHARK 12/01/16 10:57:43 AM
#2300   What is the reason ? Is it to too simple 11/30/16 05:58:39 PM
#2299   I recharacterized the Roth IRA back to the SJSTOCKSHARK 11/30/16 12:24:08 PM
#2298   Iluv, There are other ways to finance that SJSTOCKSHARK 11/18/16 05:03:17 PM
#2297   And don't forget, they will need more money iloveu2 11/18/16 11:58:07 AM
#2296   Vrock, Agreed, but we also have to wait SJSTOCKSHARK 11/18/16 11:38:02 AM
#2295   From resent news this company is in better vrock5656 11/18/16 10:54:24 AM
#2294   Wow,......a free-fall,.........a fire sale,.....a stock raid,...... While I saw Gpheart2016 11/18/16 10:33:39 AM
#2293   Gp, Until we make substantial movement in our SJSTOCKSHARK 11/17/16 09:01:36 PM
#2292   I'm getting a bit tired of these new Gpheart2016 11/17/16 10:55:56 AM
#2291   This very well may go back under $1.00 again. iloveu2 11/17/16 09:49:01 AM
#2290   I wish I was the one who was wrong! BPTH2008 11/16/16 05:12:13 PM
#2289   Uggghh, I was wrong again! Good call. dmoffat 11/16/16 11:30:45 AM
#2288   I personally think we may continue down a BPTH2008 11/15/16 07:49:46 PM
#2287   Tomorrow will be an up day with good dmoffat 11/15/16 07:02:30 PM
#2286   Great question, SJ. I don't know where to Gpheart2016 11/13/16 10:20:51 AM
#2285   Too and GP. It is nice to see SJSTOCKSHARK 11/12/16 12:55:12 PM
#2284   Big volume indicates that this company has really Gpheart2016 11/12/16 10:29:54 AM
#2283   SJ , yes thank you for posting when too simple 11/12/16 08:39:02 AM
#2282   A substantial increase in volume! SJSTOCKSHARK 11/11/16 04:54:21 PM
#2281   Gp, I am glad I made my a SJSTOCKSHARK 11/11/16 03:18:13 PM
#2280   I don't know about you guys, but I'm Gpheart2016 11/11/16 01:30:30 PM
#2279   Moffat, Nice find. SJSTOCKSHARK 11/11/16 10:48:46 AM
#2278   I just listened as I was driving, will too simple 11/11/16 09:08:16 AM
#2277   Page 13 under header "service agreement" in the dmoffat 11/10/16 11:16:05 PM
#2276   I have not read it yet but I BPTH2008 11/10/16 10:37:34 PM
#2275   My take on the conference call is not SJSTOCKSHARK 11/10/16 09:39:55 PM
#2274   Moffat, I think a show me attitude is SJSTOCKSHARK 11/10/16 10:38:23 AM
#2273   Should I allow myself to get excited about dmoffat 11/09/16 06:11:06 PM
#2272   The reason it is being shorted is because iloveu2 11/09/16 12:39:42 PM
#2271   GP, Interesting. SJSTOCKSHARK 11/08/16 03:58:30 PM
#2270   Surprisingly, there appears to be a lot of Gpheart2016 11/08/16 01:59:31 PM
#2269   Gp, I agree. In my opinion our science SJSTOCKSHARK 11/08/16 11:01:35 AM
#2268   SJ, my point was antisense technology works and Gpheart2016 11/08/16 01:09:58 AM
#2267   Gp, Ionis was formerly ISIS. They are our SJSTOCKSHARK 11/07/16 06:06:34 PM
#2266   Exciting news about antisense technology. Check out Ionis Gpheart2016 11/07/16 10:14:04 AM
#2265   more news: SJSTOCKSHARK 11/06/16 11:10:50 PM
#2264   Great news lately. So much upside with BPTH, just wingshooterr 11/04/16 09:04:59 PM
#2263   More news. It looks like the drop to SJSTOCKSHARK 11/04/16 11:52:18 AM
#2262   I find it a little strange we did vrock5656 11/04/16 09:17:22 AM
#2261   GP, Yes the news is good. My question SJSTOCKSHARK 11/03/16 12:38:32 PM
PostSubject